Centers | ||
Therapeutic Accelerator Program (TAP) | VMCC, University of Michigan | Chulalongkorn University Drug Discovery and Drug Development Research Center (Chula4DR) |
Test |
The VMCC is an on-campus core facility for the design and synthesis of drug-like molecules and diagnostic probes used in biomedical investigations. Our Mission: To assist biomedical researchers in translating novel therapeutic hypotheses into... |
Chulalongkorn
Drug Discovery and Drug Development Research Center (Chula4DR) was
established in 2017, with the aim to facilitate advancement of academic
drug discovery and drug development research by leveraging innovations
and sciences... Read more |
Partnerships |
Events |
Jobs |
Argenta and ANTABIO Announce Drug Discovery CollaborationArgenta, a Galapagos NV (Euronext: GLPG) company that provides drug discovery services from target validation to proof of concept, announced today that it has achieved a milestone with its collaboration partner Antabio in an anti-bacterial drug... View all Janssen Pharmaceuticals and Johns Hopkins To Develop New Therapies to Treat Neurological DiseasesJanssen Pharmaceuticals (Formerly OMJPI) a Johnson and Johnson entity has entered into collaboration agreement with Johns Hopkins Brain Science Institute ("BSi") at Johns Hopkins University. Janssen will be working with Johns Hopkins researchers... View all JDRF & Novo Nordisk to Collaborate on Type 1 DiabetesJDRF and Novo Nordisk have entered into collaboration to develop new immunotherapies to treat Type 1 diabetes. The new partnership will be based out of Novo's newly opened Type 1 Diabetes R&D Center in Seattle. JDRF and Novo Nordisk will be... View all |
No EVENTS for listing |
No Job Posts |


